FIGURE 1. Binding of ^99mTc-sulesomab and ^99mTc-HSA (A) and ¹⁸F-FDG (B) to quiescent control, TNF--primed, and TNF--primed, fMLP fully activated granulocytes, shown as percentage uptake of available tracer by cells (mean ± SE). ^99mTc-Sulesomab or ^99mTc-HSA was added to suspension of granulocytes after they had been incubated with TNF- (or PBS) for 30 min and exposed to fMLP (or PBS) for additional 5 min. ¹⁸F-FDG was added to suspension of granulocytes after they had been incubated with TNF- (or PBS) for 30 min and immediately before addition of fMLP (or PBS). Data are corrected for nonspecific binding (n = 3 for each column). *Significant difference compared with control cells at P < 0.05. Significant difference compared with control cells at P < 0.005.

Return to article